JP2011515349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515349A5 JP2011515349A5 JP2010550897A JP2010550897A JP2011515349A5 JP 2011515349 A5 JP2011515349 A5 JP 2011515349A5 JP 2010550897 A JP2010550897 A JP 2010550897A JP 2010550897 A JP2010550897 A JP 2010550897A JP 2011515349 A5 JP2011515349 A5 JP 2011515349A5
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- pharmaceutical composition
- composition according
- dimethylbenzyloxy
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 12
- 229940116269 uric acid Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- IYOFVSUBBMQUQM-UHFFFAOYSA-N 2-[3-[(2,6-dimethylphenyl)methoxy]-4-methylphenyl]acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1OCC1=C(C)C=CC=C1C IYOFVSUBBMQUQM-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000029142 excretion Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 108010092464 Urate Oxidase Proteins 0.000 claims 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3629408P | 2008-03-13 | 2008-03-13 | |
| US61/036,294 | 2008-03-13 | ||
| PCT/US2009/037128 WO2009151695A1 (en) | 2008-03-13 | 2009-03-13 | Compounds and method for reducing uric acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012035313A Division JP5547222B2 (ja) | 2008-03-13 | 2012-02-21 | 尿酸を減少させる化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011515349A JP2011515349A (ja) | 2011-05-19 |
| JP2011515349A5 true JP2011515349A5 (enExample) | 2012-04-12 |
| JP5339545B2 JP5339545B2 (ja) | 2013-11-13 |
Family
ID=41417026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550897A Expired - Fee Related JP5339545B2 (ja) | 2008-03-13 | 2009-03-13 | 尿酸を減少させる化合物及び方法 |
| JP2012035313A Expired - Fee Related JP5547222B2 (ja) | 2008-03-13 | 2012-02-21 | 尿酸を減少させる化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012035313A Expired - Fee Related JP5547222B2 (ja) | 2008-03-13 | 2012-02-21 | 尿酸を減少させる化合物及び方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8829058B2 (enExample) |
| EP (2) | EP3517109A1 (enExample) |
| JP (2) | JP5339545B2 (enExample) |
| KR (2) | KR101677945B1 (enExample) |
| CN (2) | CN102976928B (enExample) |
| AU (1) | AU2009258040B8 (enExample) |
| BR (2) | BRPI0924547B1 (enExample) |
| CA (1) | CA2716860C (enExample) |
| DK (1) | DK2268141T3 (enExample) |
| ES (1) | ES2741153T3 (enExample) |
| IL (2) | IL208004A (enExample) |
| MX (2) | MX2010009959A (enExample) |
| NZ (2) | NZ602321A (enExample) |
| RU (2) | RU2501554C2 (enExample) |
| UA (2) | UA109638C2 (enExample) |
| WO (1) | WO2009151695A1 (enExample) |
| ZA (1) | ZA201005872B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8829058B2 (en) | 2008-03-13 | 2014-09-09 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| MX2010011603A (es) | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
| WO2011046800A1 (en) * | 2009-10-13 | 2011-04-21 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
| US20130331452A1 (en) | 2010-09-08 | 2013-12-12 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| JP5990106B2 (ja) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
| WO2012125533A1 (en) * | 2011-03-14 | 2012-09-20 | Wellstat Therapeutics Corporation | 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid |
| US9023856B2 (en) | 2011-11-04 | 2015-05-05 | Cymabay Therapeutics, Inc. | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent |
| US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| AU2013245675B2 (en) * | 2012-04-13 | 2017-02-09 | Cymabay Therapeutics, Inc. | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| WO2014017643A1 (ja) | 2012-07-27 | 2014-01-30 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
| WO2017083652A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | Fluorenone compound for the treatment of gout |
| US12057228B1 (en) * | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| CN106190954B (zh) * | 2016-07-25 | 2019-12-10 | 华南理工大学 | 一种高尿酸血症肝细胞模型及其构建方法 |
| CN106190953B (zh) * | 2016-07-25 | 2019-12-10 | 华南理工大学 | 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用 |
| KR101988867B1 (ko) | 2017-07-25 | 2019-06-13 | 광주과학기술원 | 금 나노입자를 이용한 요산 분해용 조성물 |
| WO2019066469A1 (ko) * | 2017-09-27 | 2019-04-04 | 경북대학교 산학협력단 | 페북소스타트 또는 토피록소스타트의 암 전이의 예방 및 치료제로서의 용도 |
| WO2021194294A1 (ko) * | 2020-03-27 | 2021-09-30 | 가톨릭대학교 산학협력단 | 자가면역질환 평가 아바타 모델 플랫폼 |
| KR102836208B1 (ko) * | 2020-03-27 | 2025-07-18 | 가톨릭대학교 산학협력단 | 통풍 동반 관절염 모델 평가 플랫폼 |
| KR102994264B1 (ko) | 2020-03-27 | 2026-07-23 | 가톨릭대학교 산학협력단 | 쇼그렌 질환 침샘 오가노이드 모델 평가 플랫폼 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2572512B1 (fr) | 1984-10-25 | 1987-09-25 | Luchaire Sa | Dispositif, adaptable sur engins ou munitions, tels que projectiles d'artillerie, destine a reduire leur trainee de culot |
| EP0279630B1 (en) | 1987-02-16 | 1993-10-13 | Konica Corporation | Developer for light-sensitive lithographic printing plate capable of processing commonly the negative-type and the positive type and developer composition for light-sensitive material |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
| AU4953796A (en) | 1995-03-15 | 1996-10-02 | Sanyko Company, Limited | Dipeptide compounds having ahpba structure |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| WO2001036351A2 (en) * | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| RU2341513C2 (ru) * | 2001-06-12 | 2008-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических заболеваний |
| CA2502297C (en) * | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2530235T3 (es) * | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| ES2353601T3 (es) * | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| CA2522738C (en) | 2003-04-30 | 2011-11-08 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| TWI280136B (en) * | 2003-05-30 | 2007-05-01 | Lytone Enterprise Inc | Composition containing dipeptide of histidine and alanine for reducing uric acid |
| RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| DE602005004988T2 (de) * | 2004-11-15 | 2009-03-26 | The Pilot Ink Co., Ltd., Nagoya | Reversibele thermochromische Zusammensetzung und Mikrokapseln, die diese enthalten |
| AR051780A1 (es) | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| UA95613C2 (ru) | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| AU2007208127A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
| US7838556B2 (en) * | 2006-02-21 | 2010-11-23 | University Of Maryland, Baltimore | Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands |
| WO2007117791A2 (en) * | 2006-03-31 | 2007-10-18 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
| US20100234464A1 (en) * | 2006-06-09 | 2010-09-16 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CA2661293A1 (en) * | 2006-08-17 | 2008-02-21 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
| WO2009091732A1 (en) | 2008-01-15 | 2009-07-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8829058B2 (en) | 2008-03-13 | 2014-09-09 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| MX2010011603A (es) | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
| US20130331452A1 (en) | 2010-09-08 | 2013-12-12 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
-
2009
- 2009-03-13 US US12/920,555 patent/US8829058B2/en active Active
- 2009-03-13 BR BRPI0924547-2A patent/BRPI0924547B1/pt not_active IP Right Cessation
- 2009-03-13 RU RU2010141823/15A patent/RU2501554C2/ru active
- 2009-03-13 EP EP19158335.0A patent/EP3517109A1/en active Pending
- 2009-03-13 JP JP2010550897A patent/JP5339545B2/ja not_active Expired - Fee Related
- 2009-03-13 CN CN201210548148.XA patent/CN102976928B/zh not_active Expired - Fee Related
- 2009-03-13 ES ES09762990T patent/ES2741153T3/es active Active
- 2009-03-13 WO PCT/US2009/037128 patent/WO2009151695A1/en not_active Ceased
- 2009-03-13 NZ NZ60232109A patent/NZ602321A/xx not_active IP Right Cessation
- 2009-03-13 DK DK09762990.1T patent/DK2268141T3/da active
- 2009-03-13 UA UAA201202932A patent/UA109638C2/ru unknown
- 2009-03-13 BR BRPI0909299-4A patent/BRPI0909299B1/pt not_active IP Right Cessation
- 2009-03-13 CA CA2716860A patent/CA2716860C/en not_active Expired - Fee Related
- 2009-03-13 MX MX2010009959A patent/MX2010009959A/es active IP Right Grant
- 2009-03-13 AU AU2009258040A patent/AU2009258040B8/en not_active Ceased
- 2009-03-13 CN CN200980108707.1A patent/CN101969773B/zh not_active Expired - Fee Related
- 2009-03-13 RU RU2012110592/15A patent/RU2501555C2/ru active
- 2009-03-13 KR KR1020147023462A patent/KR101677945B1/ko not_active Expired - Fee Related
- 2009-03-13 NZ NZ587433A patent/NZ587433A/xx not_active IP Right Cessation
- 2009-03-13 MX MX2013011790A patent/MX342806B/es unknown
- 2009-03-13 EP EP09762990.1A patent/EP2268141B1/en active Active
- 2009-03-13 KR KR1020107021875A patent/KR101677944B1/ko not_active Expired - Fee Related
- 2009-03-13 UA UAA201012059A patent/UA103894C2/ru unknown
-
2010
- 2010-08-17 ZA ZA2010/05872A patent/ZA201005872B/en unknown
- 2010-09-06 IL IL208004A patent/IL208004A/en active IP Right Grant
-
2012
- 2012-02-21 JP JP2012035313A patent/JP5547222B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-09 US US13/890,789 patent/US9115072B2/en active Active - Reinstated
-
2016
- 2016-08-07 IL IL247136A patent/IL247136B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519865A5 (enExample) | ||
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| KR101567885B1 (ko) | 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물 | |
| US20070105894A1 (en) | Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor | |
| JP2022537570A (ja) | がんを処置する方法 | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2012184234A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| JP2016164165A5 (enExample) | ||
| JP2011520965A5 (enExample) | ||
| ES2449340T3 (es) | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales | |
| BRPI0910541B8 (pt) | compostos de tetrazol | |
| AU2020201980A1 (en) | Combination of FXR agonists | |
| JP2014532758A5 (enExample) | ||
| JP2013507438A5 (enExample) | ||
| NZ624708A (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| EA200601286A1 (ru) | Фармацевтические композиции, содержащие ингибитор протонового насоса и прокинетический агент | |
| JP5439817B2 (ja) | 尿排出障害治療剤 | |
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| JP7658909B2 (ja) | 筋ジストロフィー治療薬 | |
| TW201215389A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| US9084769B2 (en) | Compositions comprising non steroidal anti-inflammatory drugs and methods for use thereof | |
| ES2779724T3 (es) | Prevención y/o agente terapéutico para la fibromialgia | |
| WO2014117117A1 (en) | Chronic nsaid treatment for fuchs endothelial corneal dystrophy |